Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
1996

Effects of ICI 182780 in Advanced Breast Cancer

Sample size: 19 publication Evidence: moderate

Author Information

Author(s): A Howell, D J DeFriend, J F R Robertson, R W Blamey, L Anderson, E Anderson, F A Sutcliffe, P Walton

Primary Institution: University of Manchester

Hypothesis

Can ICI 182780 be an effective treatment for advanced breast cancer resistant to tamoxifen?

Conclusion

ICI 182780 is an active second-line anti-oestrogen with a high response rate and long duration of effect in women with advanced breast cancer resistant to tamoxifen.

Supporting Evidence

  • Thirteen (69%) patients responded to ICI 182780 after progression on tamoxifen.
  • The median duration of response was 25 months.
  • ICI 182780 did not induce significant side effects such as hot flushes or vaginal dryness.
  • Serum levels of FSH and LH increased significantly during treatment.

Takeaway

This study tested a new medicine called ICI 182780 on women with breast cancer that didn't get better with another medicine. Most of the women felt better for a long time without many side effects.

Methodology

Nineteen post-menopausal women with advanced breast cancer resistant to tamoxifen were treated with ICI 182780 administered as a monthly depot intramuscular injection.

Potential Biases

Potential selection bias due to the specific inclusion criteria for participants.

Limitations

The study had a small sample size and was limited to post-menopausal women.

Participant Demographics

Nineteen post-menopausal women with advanced breast cancer.

Statistical Information

P-Value

p<0.005 for LH increase

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication